The Clinical Stage Partnering Terms and Agreements
2010-2015 report provides comprehensive understanding and unprecedented access
to the clinical stage partnering deals and agreements entered into by the
worlds leading healthcare companies
Description
The Clinical Stage Partnering Terms and Agreements
2010-2015 report provides comprehensive understanding and unprecedented access
to the clinical stage partnering deals and agreements entered into by the
worlds leading healthcare companies.
The report provides a detailed understanding and
analysis of how and why companies enter clinical stage partnering deals. The
majority of deals are where the licensee obtains a right or an option right to
license the licensors product or compound. These deals tend to be multicomponent,
starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective
partner’s negotiated deals terms provides critical insight into the negotiation
process in terms of what you can expect to achieve during the negotiation of
terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered –
contract documents provide this insight where press releases do not.
This report contains over 1,700 links to online
copies of actual clinical stage deals and contract documents as submitted to
the Securities Exchange Commission by companies and their partners. Contract
documents provide the answers to numerous questions about a prospective
partner’s flexibility on a wide range of important issues, many of which will
have a significant impact on each party’s ability to derive value from the
deal.
The initial chapters of this report provide an
orientation of clinical stage deal making and business activities.
Chapter 1 provides an introduction to the report,
whilst
Chapter 2 provides an overview of why companies
partner clinical stage compounds/products.
Chapter 3 provides an overview of clinical stage
deals strategy and deal structure including numerous case studies.
Chapter 4 provides an overview of the various
payment strategies used in clinical stage deals.
Chapter 5 provides a review of clinical stage deal
making since 2010. Deals are listed by headline value, signed by bigpharma,
most active bigpharma, and most active of all biopharma companies. Where the
deal has an agreement contract published at the SEC a link provides online
access to the contract.
Chapter 6 provides a detailed analysis of clinical
stage payment terms including average headline, upfront, milestone and royalty
rates for phase I, phase II and phase III deals.
Chapter 7 provides a review of the leading clinical
stage deal by headline value.
Chapter 8 provides a comprehensive listing of the
top 50 big pharma and big biotech companies with a brief summary followed by a
comprehensive listing of clinical stage deals, as well as contract documents
available in the public domain. Where available, each deal title links via
Weblink to an online version of the actual contract document, providing easy
access to each contract document on demand.
Chapter 9 provides a comprehensive and detailed
review of clinical stage partnering deals signed and announced since 2010,
where a contract document is available in the public domain. The chapter is
organized by company A-Z, stage of development at signing, deal type
(collaborative R&D, co-promotion, licensing etc), and specific therapy
focus. Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy access to
each contract document on demand.
Chapter 10 provides a comprehensive directory of
clinical stage partnering deals since 2010 organized by stage of development –
phase I, phase II and phase III.
The report also includes numerous tables and
figures that illustrate the trends and activities in clinical stage partnering
and deal making since 2010.
In addition, a comprehensive appendix is provided
organized by partnering company A-Z, deal type, therapy focus and technology
type. Each deal title links via Weblink to an online version of the deal record
and where available, the contract document, providing easy access to each
contract document on demand.
In conclusion, this report provides everything a
prospective dealmaker needs to know about partnering in the research,
development and commercialization of clinical stage products and compounds.
Benefits
Clinical Stage Partnering Terms and Agreements
2010-2015 provides the reader with the following key benefits:
- In-depth understanding of clinical stage deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 1,700 clinical stage deals together with contract documents if available
- Detailed access to actual clinical stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
- Analysis of the structure of clinical stage agreements with numerous real life case studies
- Identify leading clinical stage deals by value since 2010
- Identify the most active clinical stage dealmakers since 2010
- Full listing of clinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 2159 pages and 28
Figures “Clinical
Stage Partnering Terms and Agreements 2010-2015” report covers Executive
Summary, Introduction, Why do companies partner clinical stage compounds?,
Clinical stage deal strategies and structure, Clinical stage partnering payment
strategies, Trends in clinical stage deal making, Average payment terms for
clinical stage partnering, Leading clinical stage deals, Big pharma and big
biotech clinical stage partnering deals, Clinical stage partnering contracts
directory, Clinical stage dealmaking by development stage, Appendix.
Find
more information Visit at: http://mrr.cm/o6h
Find all Pharma and Healthcare Report visit at - http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.